III期临床出炉,成功减重18.3kg!最新研究:“减肥神药”司美格鲁肽竟还有抗癌、降痴呆作用
上回说到,最近爆火的“减肥神药”司美格鲁肽(Semaglutide)传来好消息:口服版III期临床数据显示,司美格鲁肽能够高效减糖减重,甚至无需注射(详情可见:高效减重15kg?“减肥神药”口服版III期临床试验成功!背后是.......)。
NOVO NORDISK官网
GLP-1疗法增加了肥胖患者中的NK细胞效应子功能
doi: 10.1002/trc2.12268
参考文献:
[1]https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166110
[2]Khoo TK, Lin J. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;385(1):e4. doi:10.1056/NEJMc2106918
[3]De Barra C, Khalil M, Mat A, O'Donnell C, Shaamile F, Brennan K, O'Shea D, Hogan AE. Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function. Obesity (Silver Spring). 2023 May 9. doi: 10.1002/oby.23772. Epub ahead of print. PMID: 37157931.
[4]Nørgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Møller DV, Knudsen LB, Kvist K, Zinman B, Holm E, Torp-Pedersen C, Mørch LS. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement (N Y). 2022 Feb 23;8(1):e12268. doi: 10.1002/trc2.12268. PMID: 35229024; PMCID: PMC8864443.
微信扫码关注该文公众号作者